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Dermatitis herpetiformis is a gluten-sensitive disease
with a symmetrically distributed blistering over
extensor surfaces. The association with celiac disease
is further supported by the high rate of immuno-
globulin A autoantibodies to endomysium in patients
with dermatitis herpetiformis, which are highly specific
and sensitive indicators of celiac disease. Therefore,
we determined immunoglobulin A antibodies to tissue
transglutaminase, the recently discovered endomysial
autoantigen in celiac disease, in patients with derma-
titis herpetiformis and controls. Sera of 61 patients
with dermatitis herpetiformis, as characterized by
granular immunoglobulin A deposits in the sub-
epidermal basement membrane and known endo-
mysial antibody titers (determined by indirect
immunofluorescence) as well as 84 control sera of
patients with dermal or intestinal diseases unrelated to
dermatitis herpetiformis, were analyzed for circulating
Dermatitis herpetiformis (DH) manifests as a life-longblistering skin disease with a rash on elbows, knees,and buttocks, combined with disease-specific granu-lar immunoglobulin (Ig)A deposits in the basementmembrane zone of uninvolved skin areas (van der
Meer, 1969). These IgA deposits were shown to be polyclonal and
mainly composed of IgA1, but the existence of IgA2 suggests that
they are in part of mucosal origin (Wojnarowska et al, 1988).
Although patients with DH rarely complain of severe gastro-
intestinal symptoms, approximately 80% of them have a gluten-
sensitive enteropathy, i.e., celiac disease (CD), characterized by
villus atrophy or at least an increased number of intraepithelial
lymphocytes (Gawkrodger et al, 1984; Savilahti et al, 1992).
In addition, patients with DH share the same immunogenetic
background as patients with CD which is strongly associated with
human leukocyte antigen DQw2 (Reunala and Ma¨ki, 1993). The
skin eruptions as well as the enteropathy improve on a gluten-free
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immunoglobulin A antibodies to tissue transglut-
aminase by enzyme-linked immunosorbent assay.
Immunoglobulin A anti-tissue transglutaminase titers
in patients with dermatitis herpetiformis were sig-
nificantly elevated above the controls. Furthermore,
the immunoglobulin A anti-tTG titers showed a
positive correlation with semiquantitative endomysial
antibody data. Compared with endomysial antibodies,
determination of immunoglobulin A anti-tissue trans-
glutaminase reached a specificity and sensitivity of
97.6% and 89.1%. Patients with dermatitis herpeti-
formis have elevated immunoglobulin A autoanti-
bodies to tissue transglutaminase, confirming its
pathogenic relation with celiac disease and further
supporting the usefulness of this novel assay for screen-
ing and therapy control. Key words: autoantibody/celiac
disease/enzyme-linked immunosorbent assay/endomysial
antibody. J Invest Dermatol 113:133–136, 1999
diet (Fry et al, 1973; Reunala et al, 1977), thus emphasizing the
association of DH with gluten exposure and CD.
In this line, serum IgA antibodies to gliadins, wheat proteins
that trigger CD in genetically predisposed individuals, are found
both in patients with CD and DH, showing some correlation to
intestinal mucosal damage (Unsworth et al, 1981; Volta et al, 1984).
More important, circulating IgA antibodies to endomysium, a
specialized perimuscular connective tissue, are also detectable in
both diseases (Chorzelski et al, 1984; Kumar et al, 1984; Seah et al,
1991). These endomysial autoantibodies (EMA) are considered the
most sensitive and specific markers for small intestinal pathology
(Beutner et al, 1986; Reunala et al, 1987; Ha¨llstro¨m, 1989).
Recently, we identified tissue transglutaminase (tTG) as the
endomysial autoantigen in patients with CD (Dieterich et al, 1997),
and an enzyme-linked immunosorbent assay (ELISA) to detect
serum IgA anti-tTG offers the opportunity to quantitate these
autoantibodies in sera of these patients and to monitor antibody
titers for therapy control (Dieterich et al, 1998).
In order to explore further the relation between DH and CD
and the role of tTG as autoantigen, we studied patients with DH
and controls for IgA anti-tTG titers. Antibody levels were compared
with semiquantitative EMA titers obtained by indirect immuno-
fluorescence on sections of monkey esophagus.
MATERIALS AND METHODS
Patients Sixty-one DH patients on a normal diet (33 females and 28
males, median age 36.3 y, range 6–87 y) with granular IgA deposits in the
134 DIETERICH ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
skin and known titers of IgA anti-endomysium autoantibodies as determined
by indirect immunofluorescence on cryosections of monkey esophagus,
were examined. In addition, eight patients with positive IgA anti-tTG
titers at first diagnosis were followed-up over 4–24 mo on a gluten-free diet.
Eighy-four persons (56 females and 28 males, median age 32.1 y, range
1–81 y) served as controls including nine healthy individuals, 40 patients
with various malabsorption syndromes unrelated to CD (i.e., somatomental
retardation, toddler’s diarrhea, egg, soya, or lactose intolerance, viral
infection, gastroesophageal reflux disease, inflammatory bowel disease,
giardiasis, sideropenia, bacterial small bowel contamination, recurrent
abdominal pain, alimentary dystrophy, hepatosplenomegaly, hepatocellular
carcinoma or Down’s syndrome), six with cutaneous lupus erythematosus,
16 with pemphigus vulgaris or pemphigoid, three with lichen planus, four
with eczema, two with urticaria, and one patient each with parapsoriasis,
metastasizing melanoma, xanthelasma, and facial erythema.
ELISA for tTG The ELISA to quantitate the IgA antibodies directed
to tTG was performed as described previously, with some modifications
(Dieterich et al, 1997, 1998). Briefly, microtiter plates were coated with
tTG (1 µg per well, 0.00167 units per µg) from guinea pig liver (Sigma,
Deisenhofen, Germany) in 50 mM Tris–HCl, 150 mM NaCl, 5 mM
CaCl2, pH 7.5, for 2 h at 37°C. After washing with 50 mM Tris–HCl,
Table I. IgA anti-tTG and EMA titers of the 61 patients
with DH and of the 84 controls
IgA anti-tTG
No. of
IgA EMA patients Negative Positive
Patients with DH 0 15 13 2
1/5–1/20 17 2 15
1/40–1/80 26 3 23
1/100 3 0 3
Controls 0 84 82 2
Figure 1. IgA anti-tTG titers of patients with DH
and controls. (a) The medians (25/75 percentiles) were
2.0 (1.0/4.0) for controls and 43.0 (11.0/72.0) for patients
with DH (p , 0.001 between groups). (b) Correlation
of EMA titers and IgA anti-tTG titers of patients with
DH and controls (r 5 0.792; p , 0.001).
150 mM NaCl, 10 mM EDTA, 0.1% Tween-20, pH 7.4, the plates were
incubated with the sera diluted 1/25 in the same buffer for 1 h at room
temperature, washed, and incubated with peroxidase-conjugated antihuman
IgA (Dianova, Hamburg, Germany) diluted 1/1000 in the same buffer.
Color was developed in 0.1 M sodium citrate, 1 mg per ml o-phenylene-
diamine-hydrochloride, 0.06% H2O2, pH 4.2, at room temperature in the
dark for 30 min and absorbance was read at 450 nm. Anti-tTG titers were
calculated after subtraction of the background values (usually below
0.08 OD) from the optical densities and multiplication with the serum
dilution.
Statistics The Spearman test was used to correlate the anti-tTG titers
with the endomysial data derived from indirect immunofluorescence on
monkey esophagus. The Mann–Whitney U test was performed to analyze
differences of anti-tTG titers of patients with DH and controls.
RESULTS
Sera of 61 patients with DH and 84 controls with various
dermatologic disorders, part of them mimicking DH, or malabsorp-
tion syndromes were checked for the presence of IgA anti-tTG
antibodies and the data are summarized in Table I.
In 46 patients with DH, EMA as determined by indirect
immunofluorescence studies, were detectable and 41 of these also
showed elevated IgA anti-tTG titers. The remaining 15 patients
with DH had no IgA EMA. Two of them, however, showed raised
IgA anti-tTG titers.
Considering an elevated EMA titer as the recognized, noninvasive
predictor of gluten-sensitive enteropathy in patients with DH, the
sensitivity of the IgA anti-tTG ELISA was 89.1% and the specificity
97.6%, when a cut-off value of .15 for positive IgA anti-tTG
titers was chosen, which excluded 98% of nonceliacs.
Compared with the controls the patients with DH displayed a
significantly higher median of IgA anti-tTG titers (43.0 vs 2.0,
p , 0.001) (Fig 1a). When the IgA anti-tTG titers were plotted
VOL. 113, NO. 1 JULY 1999 AUTOANTIBODIES TO TISSUE TRANSGLUTAMINASE 135
Figure 2. IgA anti-tTG titers of eight patients with DH on normal
diet and after a gluten-free diet for 4–24 mo.
against EMA scores, a significant and positive correlation with r 5
0.7917 became evident (Fig 1b).
Compared with patients with CD with a median titer of 199
for IgA anti-tTG (Dieterich et al, 1998), however, most of the
patients with DH showed markedly lower IgA anti-tTG titers
(median titers of 43), quite in accordance with the low EMA titers.
Follow-up sera were available from eight DH patients with
raised IgA anti-tTG titers at the time of diagnosis. Six follow-up
sera showed a decline of IgA anti-tTG titers when patients adhered
to a strict gluten-free diet for 5–24 mo. In the two remaining
patients, who were on a gluten-free diet for a shorter time (4 and
6 mo), there was no decrease of IgA anti-tTG titers (Fig 2).
DISCUSSION
We recently identified tTG as the endomysial autoantigen of CD.
Patients with DH, a blistering skin disorder that is closely associated
with small intestinal lesions indistinguishable from CD, also display
endomysial autoantibodies. In this study we could demonstrate a
good positive correlation between IgA anti-tTG titers and the
semiquantitative EMA titers as determined by indirect immuno-
fluorescence on sections of monkey esophagus. In view of tTG as
the CD autoantigen this further supports the presumed common
pathogenesis in DH and CD. Our study suggests that the quantitative
ELISA is a valuable tool to detect and monitor patients with DH
and that this test based on tTG can replace the semiquantitative,
subjective and time-consuming immunofluorescence test on mon-
key esophagus. As in patients with DH adherence to a gluten-free
diet, which usually leads to regression of the celiac small intestinal
lesions, is not only associated with a decreased requirement for
dapsone in treatment of the skin eruptions (Fry et al, 1973;
Gawkrodger et al, 1984; Seah et al, 1991) but also with a decreased
risk in developing lymphoma (Collin et al, 1996; Lewis et al, 1996),
the ELISA for IgA anti-tTG is also useful to monitor the therapy
response and the dietary compliance when patients are subjected
to this diet.
There is increasing evidence that CD is a prerequisite for the
skin lesions of DH (Reunala, 1996). It remains unknown, however,
why the incidence of DH in patients with CD is relatively low,
reaching 20%–30% in a recent report (Collin et al, 1997).
tTG accepts dietary gliadin as a preferred substrate catalyzing the
formations of gliadin–gliadin cross-links as well as the incorporation
of gliadin into complexes with other proteins and tTG itself. The
thus created antigenic neo-epitopes may play a central part in the
pathogenesis of CD (Schuppan et al, 1998). Recently, it was
demonstrated that tTG can catalyze the deamidation of glutamine
residues in gliadin peptides (Molberg et al, 1998; Van de Wal et al,
1998). Deamidation potentiates the antigenic properties of gliadin
peptides by creating a negatively charged anchor residue for the
human leukocyte antigen DQw2 molecules.
Furthermore, the IgA antibodies to endomysium have been
suggested to affect directly the pathogenesis of CD (Beutner et al,
1986; Ma¨ki, 1996; Picarelli et al, 1996). It remains to be shown,
however, what part tTG or antibodies directed against this enzyme,
play in the development of DH.
The existence of IgA anti-tTG antibodies in DH does not
necessarily mean that the granular IgA deposits in skin, which
represent immune complexes, are due to excess antibodies reacting
with tTG or tTG-containing complexes. It is possible that these
antibodies derive from cross-reactivity with another yet unidentified
(epidermal) transglutaminase, such as a newly described transglut-
aminase (Aeschlimann et al, 1998). Such a (limited) cross-reactivity
could be a plausible explanation for the moderate penetrance of
skin eruptions in patients with CD.
Interestingly, tTG has been shown to be involved in the
intermolecular cross-linking of collagen type VII, the major com-
ponent of anchoring fibrils of skin (Raghunath et al, 1996). Collagen
VII connects the subepidermal basement membrane to the dermis
in a region, in which the IgA deposits of DH are found. Future
studies will show if there is also a dermal autoantigen in DH related
to tTG, the autoantigen in CD.
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